Mazdutide Compared to Dulaglutide in Chinese Type 2 Diabetes Patients
A phase 3 study in Chinese adults with type 2 diabetes found that mazdutide, a dual glucagon and GLP-1 receptor agonist, was more effective than dulaglutide in reducing HbA1c and body weight over 28 weeks, with manageable gastrointestinal side effects.
